Wijith Munasinghe

1.6k total citations
47 papers, 950 citations indexed

About

Wijith Munasinghe is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Wijith Munasinghe has authored 47 papers receiving a total of 950 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 17 papers in Genetics and 14 papers in Hematology. Recurrent topics in Wijith Munasinghe's work include Multiple Myeloma Research and Treatments (12 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Cancer Treatment and Pharmacology (9 papers). Wijith Munasinghe is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Cancer Treatment and Pharmacology (9 papers). Wijith Munasinghe collaborates with scholars based in United States, Australia and Netherlands. Wijith Munasinghe's co-authors include Hao Xiong, Kyle D. Holen, Ahmed Hamed Salem, Jeremy A. Ross, Andrew W. Roberts, Shaji Kumar, Peter Ansell, Sari H. Enschede, Paulo Maciag and Asher Chanan‐Khan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Wijith Munasinghe

46 papers receiving 940 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wijith Munasinghe United States	17	464	438	357	334	140	47	950
Georgios Z. Rassidakis United States	17	414 0.9×	489 1.1×	207 0.6×	231 0.7×	375 2.7×	34	1.0k
Pei Lin United States	14	512 1.1×	471 1.1×	267 0.7×	717 2.1×	180 1.3×	25	1.2k
Amanda Copeland United States	15	623 1.3×	536 1.2×	315 0.9×	116 0.3×	558 4.0×	36	1.2k
Cecilia Carpio Spain	15	388 0.8×	214 0.5×	200 0.6×	110 0.3×	270 1.9×	55	774
Cheryl Kefauver United States	17	241 0.5×	599 1.4×	173 0.5×	443 1.3×	100 0.7×	35	1.3k
Floris Dammeijer Netherlands	9	389 0.8×	284 0.6×	329 0.9×	130 0.4×	198 1.4×	15	953
Mirosław Majewski Poland	16	456 1.0×	522 1.2×	279 0.8×	308 0.9×	353 2.5×	28	1.4k
Ruth Seggewiss‐Bernhardt Germany	12	409 0.9×	434 1.0×	152 0.4×	87 0.3×	77 0.6×	19	889
Oliver Weigert Germany	20	657 1.4×	403 0.9×	403 1.1×	157 0.5×	788 5.6×	74	1.3k

Countries citing papers authored by Wijith Munasinghe

Since Specialization

Citations

This map shows the geographic impact of Wijith Munasinghe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wijith Munasinghe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wijith Munasinghe more than expected).

Fields of papers citing papers by Wijith Munasinghe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wijith Munasinghe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wijith Munasinghe. The network helps show where Wijith Munasinghe may publish in the future.

Co-authorship network of co-authors of Wijith Munasinghe

This figure shows the co-authorship network connecting the top 25 collaborators of Wijith Munasinghe. A scholar is included among the top collaborators of Wijith Munasinghe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wijith Munasinghe. Wijith Munasinghe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shimizu, Toshio, Kan Yonemori, Yasutoshi Kuboki, et al.. (2023). MO38-1 Phase 1 study of ABBV-155 ± paclitaxel in relapsed/refractory solid tumors: Results in Japanese patients. Annals of Oncology. 34. S1420–S1420. 1 indexed citations

Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2021). A Phase 1 and Biodistribution Study of ABT-806i, an ¹¹¹In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. Journal of Nuclear Medicine. 62(6). 787–794. 15 indexed citations

Munasinghe, Wijith, et al.. (2021). Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir/Ritonavir. Journal of Pharmaceutical Sciences. 110(12). 3963–3968. 7 indexed citations

Maitland, Michael L., Sarina A. Piha‐Paul, Gerald S. Falchook, et al.. (2018). Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. British Journal of Cancer. 118(8). 1042–1050. 18 indexed citations

Gray, Heidi J., Katherine M. Bell‐McGuinn, Gini F. Fleming, et al.. (2018). Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecologic Oncology. 148(3). 507–514. 58 indexed citations

Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2017). A Phase 1 and Biodistribution Study of Abt-806I, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-Egfr Antibody Abt-806. Internal Medicine Journal. 47. 13–13. 2 indexed citations

Nuthalapati, Silpa, Wijith Munasinghe, Vincent L. Giranda, & Hao Xiong. (2017). Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. Clinical Pharmacokinetics. 57(1). 51–58. 16 indexed citations

Czito, Brian G., Dustin A. Deming, Gayle Jameson, et al.. (2017). Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. The Lancet. Gastroenterology & hepatology. 2(6). 418–426. 53 indexed citations

Munasinghe, Wijith, Rajendar K. Mittapalli, Hong Li, et al.. (2017). Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR. Cancer Chemotherapy and Pharmacology. 79(5). 915–922. 10 indexed citations

10.

Gan, Hui, David A. Reardon, Andrew B. Lassman, et al.. (2017). Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro-Oncology. 20(6). 838–847. 57 indexed citations

11.

Cheung, TT, Ahmed Hamed Salem, Rajeev Menon, et al.. (2017). Pharmacokinetics of the BCL‐2 Inhibitor Venetoclax in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 7(4). 435–440. 23 indexed citations

12.

Reardon, David A., Andrew B. Lassman, Martin J. van den Bent, et al.. (2016). Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology. 19(7). now257–now257. 86 indexed citations

13.

Moreau, Philippe, Asher Chanan‐Khan, Andrew W. Roberts, et al.. (2016). Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. Blood. 128(22). 975–975. 18 indexed citations

14.

Munasinghe, Wijith, Anthony W. Tolcher, Emiliano Calvo, et al.. (2016). Abstract CT149: Assessment of the cardiac safety of veliparib in a thorough QT/QTc study at therapeutic doses in patients with relapsed/refractory solid tumors: a randomized, placebo-controlled crossover study. Cancer Research. 76(14_Supplement). CT149–CT149. 1 indexed citations

15.

Cleary, James M., David A. Reardon, Nilofer S. Azad, et al.. (2015). A phase 1 study of ABT-806 in subjects with advanced solid tumors. Investigational New Drugs. 33(3). 671–678. 28 indexed citations

16.

Gan, Hui, Priya Kumthekar, Andrew B. Lassman, et al.. (2015). ATNT-01ABT-414 MONO- OR COMBINATION THERAPY WITH TEMOZOLOMIDE (TMZ) RECHALLENGE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) AND AMPLIFIED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR): A PHASE I STUDY. Neuro-Oncology. 17(suppl 5). v10.1–v10. 2 indexed citations

17.

Touzeau, Cyrille, Asher Chanan‐Khan, Andrew W. Roberts, et al.. (2015). Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).. Journal of Clinical Oncology. 33(15_suppl). 8580–8580. 3 indexed citations

18.

Michael, Michael, Mary F. Mulcahy, Dustin A. Deming, et al.. (2015). Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer (LARC): Final results of a phase Ib study.. Journal of Clinical Oncology. 33(15_suppl). 3517–3517. 7 indexed citations

19.

Garcia‐Manero, Guillermo, Raoul Tibes, Tapan M. Kadia, et al.. (2015). Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Investigational New Drugs. 33(4). 870–880. 20 indexed citations

20.

Ma, Shuo, John F. Seymour, Mark C. Lanasa, et al.. (2014). ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.. Journal of Clinical Oncology. 32(15_suppl). 7013–7013. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact